Skip to main content

Table 1 Patients’ clinical data vs polymorphisms distribution

From: A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients

Parameter CYP2C19*2 P value CYP2C19*3 P value CYP2C19*17 P value
GG % GA % AA % GG % GA % AA % CC % CT % TT %
Familial antecedents     0.8     0.1     0.3
 (+) 0 100 0   0 0 100   50 50 0  
 (−) 7.1 82.1 10.8   3.9 76.5 19.6   15.4 63.1 21.5  
Personal antecedents     0.1     NC     0.002**
 (+) 16.7 72.2 11.1   4.5 68.2 27.3   3.6 57.1 39.3  
 (−) 2.5 87.5 10   0 0 0   26.3 65.8 7.9  
Blood pressure     0.3     0.9     0.3
 (+) 13 78.3 8.7   4 76 40   16.7 61.1 22.2  
 (−) 2.9 85.7 11.4   5.7 77.1 17.2   20.8 70.8 8.3  
Smoking     0.8     0.2     0.8
 (+) 8.7 82.6 8.7   8.7 82.6 8.7   16.1 64.5 19.4  
 (−) 5.7 82.9 11.4   2.7 73 24.3   12.9 61.3 25.8  
Diabetes     0.1     0.4     0.1
 (+) 14.3 71.4 14.3   8 80 12   16.1 58.1 25.8  
 (−) 2.7 89.2 8.1   2.9 74.3 22.8   11.5 80.8 7.7  
Dyslipidemia     0.5     0.5     0.1
 (+) 25 75 0   11.1 66.7 22.2   14.2 42.9 42.9  
 (−) 11.1 77.8 11.1   0 77.8 22.2   10 80 10  
  1. NC none calculated
  2. * Statistically significant (Chi square test)